Revolution Medicines's latest marketcap:
As of 08/31/2026, Revolution Medicines's market capitalization has reached $44.56 B. According to our data, Revolution Medicines is the 588th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 44.56 B |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -1,768,285,000 |
| Shares Out | 214.34 M |
| EPS (ttm) | -8.92 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/05/2026 |
Revolution Medicines's yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 08/31/2026 | $44.56 B | 120.99% | 588 |
| 12/31/2025 | $15.4 B | 90.5% | 2285 |
| 12/31/2024 | $8.08 B | 71.26% | 2055 |
| 12/29/2023 | $4.72 B | 123.15% | 2992 |
| 12/30/2022 | $2.11 B | 14.03% | 5179 |
| 12/31/2021 | $1.85 B | -29.43% | 6457 |
| 12/31/2020 | $2.63 B | 4510 |
Company Profile
Revolution Medicines, Inc. Overview
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company is headquartered in Redwood City, California, and was incorporated in 2014.
Pipeline Highlights
Revolution Medicines' research and development pipeline includes:
RAS(ON) Inhibitors
- Daraxonrasib (RMC-6236) – Phase 1 clinical trial
- Elironrasib G12C (RMC-6291) – Phase 1 clinical trial
- Zoldonrasib G12D (RMC-9805) – Phase 1 clinical trial
- Development Candidates: RMC-5127 (G12V), RMC-0708 (Q61H), RMC-8839 (G13C)
RAS Companion Inhibitors
- RMC-4630 – Phase 2 clinical trial
- RMC-5552 – Phase 1 clinical trial
The company's therapies are designed for use as monotherapy, in combination with other RAS(ON) inhibitors, or alongside RAS companion inhibitors and other therapeutic agents.
Frequently Asked Questions
-
What is Revolution Medicines's (RVMD) current market cap?As of 08/31/2026, Revolution Medicines (including the parent company, if applicable) has an estimated market capitalization of $44.56 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Revolution Medicines (RVMD) rank globally by market cap?Revolution Medicines global market capitalization ranking is approximately 588 as of 08/31/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.